AstraZeneca said its COVID-19 vaccine contributed $275 million to first-quarter sales and shaved three cents per share from its earnings, as it posted better-than-expected results and forecast growth in the second half. This is the first time the Anglo-Swedish drugmaker has given financial details of the distribution and sales of its vaccine, which it developed with Oxford University. It has said it will not make a profit from the shot during the pandemic. Vaccine revenue included delivery of about 68 million doses, AstraZeneca said on Friday, adding that sales in Europe, where it faces a legal case, were $224 million, in emerging markets $43 million and $8 million in the rest of the world.
ChinaAstraZeneca says on track to deliver on COVID shots as sales hit $275 mln
ReutersPushkala AripakaLudwig Burger
5 minute read
AstraZeneca said its COVID-19 vaccine sales were $275 million in the first-quarter and it is on track to deliver 200 million doses a month from April, as better-than-expected results and a second half growth forecast boosted its shares.
Chief Executive Pascal Soriot again defended the vaccine rollout on Friday, saying that Anglo-Swedish drugmaker had not overpromised on its ability to supply shots, as he defended big cuts in deliveries that prompted a European Union lawsuit.
AstraZeneca (AZN.L), which has said it will not make a profit from the shot during the pandemic, was reporting financial details of distribution and sales of the vaccine it developed with Oxford University for the first time.
AstraZeneca says on track to deliver on COVID shots as sales hit $275 million
By Pushkala Aripaka and Ludwig Burger
Reuters
(Reuters) -AstraZeneca said its COVID-19 vaccine sales were $275 million in the first-quarter and it is on track to deliver 200 million doses a month from April, as better-than-expected results and a second half growth forecast boosted its shares.
Chief Executive Pascal Soriot again defended the vaccine rollout on Friday, saying that Anglo-Swedish drugmaker had not overpromised on its ability to supply shots, as he defended big cuts in deliveries that prompted a European Union lawsuit.
AstraZeneca, which has said it will not make a profit from the shot during the pandemic, was reporting financial details of distribution and sales of the vaccine it developed with Oxford University for the first time.
boosted its shares.
Chief Executive Pascal Soriot again defended the vaccine rollout on Friday, saying that Anglo-Swedish drugmaker had not overpromised on its ability to supply shots, as he defended big cuts in deliveries that prompted a European Union lawsuit.
AstraZeneca, which has said it will not make a profit from the shot during the pandemic, was reporting financial details of distribution and sales of the vaccine it developed with Oxford University for the first time.
It said the revenue included delivery of about 68 million doses, adding that European sales were $224 million, emerging markets $43 million and $8 million in the rest of the world. Sales of $275 million for 68 million doses equates to a price tag of around $4 per shot.
Coronavirus latest news: AstraZeneca chief rejects EU accusations of overpromising vaccine supply to bloc yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.